search

IBBL IMIIMI is the world’s biggest public-private partnership in the field of life sciences. The initiative has a budget of €3.3 billion for the period 2014-2020 with which it funds research aiming to speed up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. On 14 December 2018, its first 10 years of funding medical breakthrough will be celebrated by an international conference and networking event taking place in Luxembourg.

IBBL is taking part in two IMI projects, LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) and CANCER-ID (Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood). LITMUS aims to develop and validate highly accurate blood tests and imaging techniques that will allow doctors and researchers to rapidly and easily diagnose the severity of the disease in individual patients and monitor changes in their livers. The objective of CANCER-ID is to develop new, less invasive ways of capturing cancerous cells and cancer genetic material from blood samples and analysing them for clues to what treatment is needed and how well drugs are working. The project focuses initially on specific types of lung and breast cancer.

Luxinnovation discussed with Kristin Kornerup, Project manager at IBBL, about the biobank’s involvement in the projects.

IBBL IMIWhat is IBBL’s contribution to these two IMI projects?

IBBL has been chosen as the central biobank of LITMUS. As such, it will gather all the biological samples currently stored at the other partners’ sites. IBBL will also serve as the central collection and storage site for the samples that will be freshly collected for the LITMUS project from at least 1,500 patients across Europe. We will store blood, plasma, serum, DNA, RNA, urine, stool and liver biopsies and create a catalogue of the samples and associated data to be made available to the research community.

In CANCER-ID, IBBL contributes to the validation of laboratory methods, the development of standard operating procedures and the development of a proficiency testing programme.

 

What kind of results are you aiming for? How do they translate to Luxembourg?

The aim of CANCER-ID is to validate the use of specific blood-based biomarkers for the early diagnosis of cancer. In addition, these could help in monitoring the efficacy of treatment, as well as helping clinicians with choosing the right treatment for the right patient at the right time.

At the national level, IBBL will bring its expertise in biobanking and biomarker validation to the EU consortia, thus increasing Luxembourg’s visibility and strengthening its reputation as a centre of excellence among internationally-renowned universities, SMEs and pharmaceutical companies. Ultimately, the results of the projects will translate into better healthcare both for European and Luxembourgish patients.

What does the IMI participation bring to IBBL?

Given the competitiveness of IMI grants, IBBL is very proud to have been selected as a partner of these two prestigious consortia. Our participation in the projects further confirms our international reputation as a reliable, quality-driven biobank and a valuable partner. Our involvement in two IMI grants has contributed to strengthening our network of partners and our growing portfolio of European and international projects.

Pictures: © IBBL

Luxinnovation is the National Contact Point for Horizon 2020, the European framework programme for research and innovation. Building on our decade-long experience of EU funding programmes, we are able to respond to questions on where to get up-to-date information on programmes and calls for project proposals, what programmes are the most suitable for you or where and how to find European partners.

Read more

Calling young scientists: Applications open for SESAR Young Scientist Award 2019

20-05-2019

Are you a young scientist undertaking research in the field of air traffic management (ATM) and aviation? Are you looking for the perfect opportunity to showcase your talent? If yes, then look no further… the SESAR Young Scientist Award is designed for people like you.
Read more

Commission invites top experts to shape new research and innovation missions

15-05-2019

The European Commission launched a call for experts to join ‘Mission Boards’, which will advise the Commission for the identification and implementation of missions in Horizon Europe, the next EU research and innovation programme.
Read more

Publication of the 2018 Luxinnovation Annual Report

07-05-2019

Luxinnovation, the national agency for the promotion of innovation, has just published its annual report for 2018: a year marked by the refinement of the agency's general strategy, more than ever at the service of Luxembourg companies, whatever their size, to support them in their innovation efforts.
Read more

2018: A successful Horizon 2020 year for Luxembourg

10-04-2019

2018 marked the entry into the last work programmes of Horizon 2020, the European Commission’s framework programme for research and innovation. Luxinnovation hosts the National Contact Point services for Horizon 2020 in Luxembourg and can look back on a productive year with exceptionally high success rates for Luxembourg applicants for Horizon 2020 funding.
Read more

Three days dedicated to mobility in Brussels

10-04-2019

Connected and automated mobility was a hot topic during the last week. While Luxembourg, France, and Germany officially launched the cross-border test bed in Schengen, Brussels hosted a two-days conference, EUCAD2019, where experts also from Luxinnovation engaged in discussions on how to ensure a fast, safe, inclusive, and trusted deployment of autonomous vehicles on European roads.
Read more

All news

Fermer